https://wiki.stamen.health/index.php?action=history&feed=atom&title=SealdSeald - Revision history2026-04-15T01:21:58ZRevision history for this page on the wikiMediaWiki 1.42.7https://wiki.stamen.health/index.php?title=Seald&diff=679&oldid=prevAdmin 3julmthh: Created with researched data2026-04-14T20:32:12Z<p>Created with researched data</p>
<p><b>New page</b></p><div>{{DISPLAYTITLE:Seald}}<br />
{{Infobox company<br />
| name = Seald AS<br />
| org_number = 917997470<br />
| founded = 2016-10-10<br />
| employees = Not disclosed<br />
| address = Norway<br />
| industry = 72.100 – Biotechnology research<br />
| website = https://www.seald.no<br />
| nht_category = Startup<br />
| description = Seald is developing an innovative approach to bile duct cancer (cholangiocarcinoma) therapeutics. An entirely new, innovative method to find a cure for bile duct cancer. Team includes board, management, advisory board, research partners, and investors.<br />
| notes = No disclosed revenue or funding. Founded 2016. Bile duct cancer (cholangiocarcinoma) is an orphan disease with limited treatment options and high unmet need.<br />
| related_companies = [[Hemispherian]], [[Exact Therapeutics]], [[Pharmasum Therapeutics]], [[Norway Health Tech]]<br />
| categories = Norway Health Tech, Startups, Biotechnology, Oncology, Rare Disease<br />
| sources = https://www.seald.no; https://data.brreg.no/enhetsregisteret/api/enheter/917997470<br />
}}<br />
<br />
== About ==<br />
<br />
Seald AS is a Norwegian biotechnology company developing novel therapeutics for bile duct cancer (cholangiocarcinoma). Founded in 2016.<br />
<br />
== Focus Area ==<br />
<br />
Bile duct cancer (cholangiocarcinoma) is a rare but aggressive cancer arising from the bile ducts. It is classified as an orphan disease with limited treatment options, particularly for advanced/metastatic disease. The company is developing an entirely new, innovative approach to treating this cancer.<br />
<br />
== Pipeline ==<br />
<br />
Seald is developing:<br />
* Technology platform for bile duct cancer<br />
* Novel therapeutic candidates<br />
<br />
== Organization ==<br />
<br />
The company has a structured organization including:<br />
* Board of Directors<br />
* Management team<br />
* Advisory Board<br />
* Research partners<br />
* Investor group<br />
<br />
== Market ==<br />
<br />
Cholangiocarcinoma (bile duct cancer) affects approximately 200,000 people globally per year. The 5-year survival rate for advanced disease is below 10%, representing significant unmet medical need. Targeted therapies and immunotherapies are active areas of development.<br />
<br />
== References ==<br />
<references/><br />
<br />
[[Category:Norway Health Tech]]<br />
[[Category:Startups]]<br />
[[Category:Biotechnology]]<br />
[[Category:Oncology]]<br />
[[Category:Rare Disease]]</div>Admin 3julmthh